Welcome!

Dear AABB attendees,
 
None of us imagined at the beginning of the year that we wouldn't be together in Baltimore sharing ideas and reconnecting, or that for the first time we would all be attending a meeting virtually.
 
While we have all in some way had to adapt to COVID-19, as larger members of the healthcare industry we can take this moment to look back with pride on the challenges we have faced and overcome this year.
 
Grifols Diagnostic division continues to support the safe and compatible transfusion of blood as we have through other global crises. Through our global leadership and commitment, you can be sure no matter how difficult the pressure you face today, we continue to support you with our innovative portfolio of transfusion medicine products designed for today's healthcare needs.
 
We look forward to coming together in person one day again. In the meantime, we sincerely hope these web pages will help you learn more about us, and most importantly our efforts supporting patient and blood supply safety.  
 
Dawn Rossin
President, Diagnostics Global Marketing
 

 

Featured Video

[Video] Grifols welcome to the virtual AABB 2020 event, including product highlights for the Procleix Panther featuring ART, Erytra, and Erytra Eflexis automated systems.

 

Company Overview

Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital, and Bio Supplies – develop, produce, and market innovative solutions and services in more than 100 countries.

As a recognized leader in transfusion medicine, the Diagnostic division shares the commitment to increase transfusion safety from donation to transfusion. The division offers a comprehensive portfolio, while helping to manage and simplify laboratory operations. Additionally, the division offers a portfolio of specialized clinical diagnostics focused on select therapeutic areas.

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership in the industry.

 

 

History Driven By Innovation

Grifols has more than 100 years of experience and knowledge in the field of transfusion medicine. Today based on this knowledge and experience we offer a full range of diagnostic solutions designed to meet your needs. 
 
 

Key milestones throughout our diagnostic history

Learn more by rolling over the image. 

A Global Leader In Transfusion Medicine

Over 32M units of blood are screened utilizing Grifols products yearly. Every day Grifols advances transfusion safety through our:

  • Leadership: We apply our extensive global expertise across the transfusion continuum.
  • Commitment: Grifols continues to strives towards ensuring safety within the transfusion chain, from donor to patient. It's in the Grifols DNA.
  • Partnership: How we work is just as important as what we deliver. Whether your center needs educational mentorship, expert workflow design, implementation support, user training or timely technical service, you have a partner that delivers support you can count on.

 

Supporting Decision Making Across The Healthcare Continuum

Screening  

  • Blood and plasma infectious disease screening

  • Donor and patient blood compatibility typing

  • Blood bags, instruments, and supplies for blood collection and separation

  • Antigen manufacturing

Diagnosis
 

  • Infectious disease

  • Autoimmunity

  • Neurodegenerative

Prognosis  

  • Blood clotting and thrombosis risk

Treatment/
Monitoring

  • Transfusion component process tracking and traceability

  • Autoimmunity testing

  • Biological drug monitoring

  • Treatment monitoring for blood thinner

This information is intended for physicians and healthcare professionals only.
 
 
ID CORE XT, ID HPA XT, ID RHD XT, BIDS XT, and ID CORE CONTROL comply with the Directive 98/79/EC of the European Parliament and of the Council on in vitro diagnostic medical devices. CE mark certification.
ID CORE XT, ID CORE CONTROL, and BIDS XT are sold in the US as IVD (FDA).
ID HPA XT and ID RHD XT are sold in the US for research use only (RUO). Not for use in diagnostic procedures.
 
Product registration and availability vary by country. For more information on product availability, please contact us here.